Compared with traditional determination of ER status through IHC, assessment results of ER status in CTCs of BC patients may provide valuable independent predictive and prognostic information for endocrine therapies, which proves that liquid biopsy may be used to stratify for benefits of endocrine therapy among patients with BC and guide therapy. The gene discussed is ESR1; the disease is breast cancer.